Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 109, Issue 3, Pages 686-693
Publisher
Springer Nature
Online
2013-07-10
DOI
10.1038/bjc.2013.360
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis
- (2013) V Damiano et al. BRITISH JOURNAL OF CANCER
- Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma
- (2012) G Sonpavde et al. BRITISH JOURNAL OF CANCER
- Overcoming resistance to tyrosine kinase inhibitors in renal cell carcinoma
- (2012) Alain Ravaud et al. CANCER TREATMENT REVIEWS
- Sequential therapy in metastatic clear cell renal carcinoma: TKI–TKI vs TKI–mTOR
- (2012) Alessandra Felici et al. Expert Review of Anticancer Therapy
- Knockdown of the nucleosome binding protein 1 inhibits the growth and invasion of clear cell renal cell carcinoma cells in vitro and in vivo
- (2012) Shi-Qi Ji et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- State of the Science: An Update on Renal Cell Carcinoma
- (2012) E. Jonasch et al. MOLECULAR CANCER RESEARCH
- Treatment selection in metastatic renal cell carcinoma: expert consensus
- (2012) Bernard Escudier et al. Nature Reviews Clinical Oncology
- Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies
- (2011) V Grünwald et al. BRITISH JOURNAL OF CANCER
- Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K-Ras Mutant Colorectal and Pancreatic Cancers
- (2011) R. Rosa et al. CLINICAL CANCER RESEARCH
- Anti-VEGF Treatment-Resistant Pancreatic Cancers Secrete Proinflammatory Factors That Contribute to Malignant Progression by Inducing an EMT Cell Phenotype
- (2011) C. Carbone et al. CLINICAL CANCER RESEARCH
- Pazopanib Efficacy in Renal Cell Carcinoma: Evidence for Predictive Genetic Markers in Angiogenesis-Related and Exposure-Related Genes
- (2011) Chun-Fang Xu et al. JOURNAL OF CLINICAL ONCOLOGY
- The expression and role of protein kinase C (PKC) epsilon in clear cell renal cell carcinoma
- (2011) Bin Huang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells
- (2011) K.-F. Chen et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma
- (2010) D. Huang et al. CANCER RESEARCH
- The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma
- (2010) D. C. Cho et al. CLINICAL CANCER RESEARCH
- Third-Line Sorafenib After Sequential Therapy With Sunitinib and mTOR Inhibitors in Metastatic Renal Cell Carcinoma
- (2010) Giuseppe Di Lorenzo et al. EUROPEAN UROLOGY
- Development and Characterization of Clinically Relevant Tumor Models From Patients With Renal Cell Carcinoma
- (2010) Jose A. Karam et al. EUROPEAN UROLOGY
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanism of Synergistic Antitumor Effect of Sorafenib and Interferon-α on Treatment of Renal Cell Carcinoma
- (2010) Ario Takeuchi et al. JOURNAL OF UROLOGY
- mTOR signaling and drug development in cancer
- (2010) Janet Dancey Nature Reviews Clinical Oncology
- Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells
- (2009) Eva Juengel et al. BMC CANCER
- Resistance to targeted therapy in renal-cell carcinoma
- (2009) Brian I Rini et al. LANCET ONCOLOGY
- Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo
- (2009) J.-Y. Liu et al. MOLECULAR CANCER THERAPEUTICS
- Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Cancer Cells
- (2008) R. Bianco et al. CLINICAL CANCER RESEARCH
- Mechanism of action of rapalogues: the antiangiogenic hypothesis
- (2008) Sandrine Faivre et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Differential Dependence of Hypoxia-inducible Factors 1α and 2α on mTORC1 and mTORC2
- (2008) Alfredo Toschi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search